Home › Ovarian Cancer › New Jersey
Ovarian Cancer clinical trials in New Jersey
40 studies for Ovarian Cancer are looking for participants at sites in New Jersey.
Cities in New Jersey
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Hunterdon Medical Center, Flemington
- Monmouth Medical Center Southern Campus, Lakewood
- Cooperman Barnabas Medical Center, Livingston
- and 6 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- John Theurer Cancer Center at Hackensack UMC, Hackensack
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Holy Name Medical Center /ID# 279017, Teaneck
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 1, 2026 · NCT07024784A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- John Theurer Cancer Center /ID# 275756, Hackensack
- Rutgers Cancer Institute of New Jersey /ID# 274358, New Brunswick
- Holy Name Medical Center /ID# 276240, Teaneck
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, East Brunswick
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Md Anderson Cancer Center At Cooper /ID# 278390, Camden
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07059845A Study of Isoquercetin in People With Ovarian Cancer
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07303894A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
RecruitingPhase 2
Ages 18 to 99 · Women · Updated Sep 15, 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Maimonides Medical Center, Short Hills
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- START New Jersey East Brunswick, East Brunswick
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06303505ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Astera Cancer Care, East Brunswick
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- START - New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081), Hackensack
- Rutgers Cancer Institute of New Jersey ( Site 0071), New Brunswick
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
- Start Njeb, East Brunswick
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 1, 2026 · NCT07736937Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- John Theurer Cancer Ctr at Hackensack Univ. Med Ctr., Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07001748A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- John Theurer Cancer Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0111, Camden
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 12, 2026 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Jersey City Medical Center, Jersey City
- and 12 more
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Summit Medical Group, Berkeley Heights
- Cooper Hospital University Medical Center, Camden
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- Hackensack University Medical Center - John Theurer Cancer Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07444814Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- MD Anderson Cancer Center at Cooper- Two Cooper Plaza, Camden
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Valley Health System, Paramus
- Holy Name, Teaneck
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06161025A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Overlook Medical Center, Summit
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Valley Health System, Paramus
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Recruiting
Ages 18 and older · Women · Updated Jul 1, 2026 · NCT05429970A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Morristown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04641247Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- Carol G. Simon Cancer Center / Atlantic Health, Morristown
RecruitingHealthy volunteers welcome
Ages 50 to 74 · Women · Updated May 6, 2026 · NCT00539162Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Holy Name Medical Center, Teaneck
RecruitingPhase 3
Ages 18 and older · Women · Updated Apr 16, 2026 · NCT05659381Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT06290193A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 11, 2026 · NCT06623396A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 18 and older · Women · Updated Feb 3, 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Brunswick
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #9, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 5, 2025 · NCT05932862From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.